AIM: To elucidate the role of overexpressed polo-like kinase1 (PLK1) in hepatocellular carcinoma (HCC). METHODS: We prospectively collected clinicopathological, immunohistochemical and semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) data from 135 HCC patients undergoing successful hepatectomy. The correlations between PLK1 mRNA expression and clinicopathologic variables were analyzed by Mann-Whitney U test. Prognostic factors were identified by univariate and multivariate analyses. RESULTS: Immunohistochemical results showed overexpression of PLK1 was mainly found in tumor tissues compared with tumor-free tissue. A similar mRNA result was obtained by semi-quantitative RT-PCR. A total of 111 samples were positive for PLK1 mRNA expression. The positive expression was correlated with venous invasion, tumor nodules and Edmondson grade. Furthermore, 1, 3, 5-year survival rates in the positive expression group were significantly lower than the negative control group. Multivariate analysis showed that positive PLK1 expression was an independent risk factor for HCC. CONCLUSION: PLK1 could be a potential biomarker for diagnosis and therapy for HCC.
AIM: To elucidate the role of overexpressed polo-like kinase1 (PLK1) in hepatocellular carcinoma (HCC). METHODS: We prospectively collected clinicopathological, immunohistochemical and semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) data from 135 HCC patients undergoing successful hepatectomy. The correlations between PLK1 mRNA expression and clinicopathologic variables were analyzed by Mann-Whitney U test. Prognostic factors were identified by univariate and multivariate analyses. RESULTS: Immunohistochemical results showed overexpression of PLK1 was mainly found in tumor tissues compared with tumor-free tissue. A similar mRNA result was obtained by semi-quantitative RT-PCR. A total of 111 samples were positive for PLK1 mRNA expression. The positive expression was correlated with venous invasion, tumor nodules and Edmondson grade. Furthermore, 1, 3, 5-year survival rates in the positive expression group were significantly lower than the negative control group. Multivariate analysis showed that positive PLK1 expression was an independent risk factor for HCC. CONCLUSION:PLK1 could be a potential biomarker for diagnosis and therapy for HCC.
Authors: Young H Kang; Jung-Eun Park; Li-Rong Yu; Nak-Kyun Soung; Sang-Moon Yun; Jeong K Bang; Yeon-Sun Seong; Hongtao Yu; Susan Garfield; Timothy D Veenstra; Kyung S Lee Journal: Mol Cell Date: 2006-11-03 Impact factor: 17.970
Authors: Phillip J Gray; David J Bearss; Haiyong Han; Raymond Nagle; Ming-Sound Tsao; Nicholas Dean; Daniel D Von Hoff Journal: Mol Cancer Ther Date: 2004-05 Impact factor: 6.261
Authors: Jörg Haupenthal; Verena Bihrer; Huedayi Korkusuz; Otto Kollmar; Christian Schmithals; Susanne Kriener; Knut Engels; Thomas Pleli; Alexander Benz; Marta Canamero; Thomas Longerich; Bernd Kronenberger; Swantje Richter; Oliver Waidmann; Thomas J Vogl; Stefan Zeuzem; Albrecht Piiper Journal: Neoplasia Date: 2012-05 Impact factor: 5.715
Authors: Shilpi Arora; Irma M Gonzales; R Tanner Hagelstrom; Christian Beaudry; Ashish Choudhary; Chao Sima; Raoul Tibes; Spyro Mousses; David O Azorsa Journal: Mol Cancer Date: 2010-08-18 Impact factor: 27.401
Authors: Stefanie A Hartsink-Segers; Carla Exalto; Matthew Allen; Daniel Williamson; Steven C Clifford; Martin Horstmann; Huib N Caron; Rob Pieters; Monique L Den Boer Journal: Haematologica Date: 2013-06-10 Impact factor: 9.941